Roth Capital lowered the firm’s price target on Cellectar Biosciences (CLRB) to $14 from $18 and keeps a Buy rating on the shares following the Q4 report. The FDA and Cellectar defined a regulatory path for iopofosine, the analyst tells investors in a research note. Roth cites model tweaks for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year
- CLRB Upcoming Earnings Report: What to Expect?
- Five new option listings and fourteen option delistings on February 23rd
- Cellectar Biosciences expands global intellectual property estate
- Cellectar Advances CLR 125 Into Early Breast Cancer Trial, Adding Depth to Its Radiotherapy Pipeline